Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients - interventional, parallel group study using home Blood Pressure monitoring
Not Applicable
Recruiting
- Conditions
- Essential hypertension
- Registration Number
- JPRN-UMIN000004491
- Lead Sponsor
- ishi-Mikawa SG-ARB association
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Allergy against irbesartan/telmisartan 2) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments 3) Impaired renal function (Cre>=2.0mg/dL) 4) Biliary obstructive disorders or level of alanine aminotransferase >= 100IU 5) Symptomatic (NYHA II, III or IV) congestive heart failure 6) Poor-controlled hypertension (SBP>=180, or DBP>=110 mmHg in office BP) 7) Severe arrythmia 8) Diabetes treated with thiazolidine 9) Malignancies or other diseases with poor prognosis 10) Pregnant 11) Subjects whose doctor in charge do not agree to join the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the changes from baseline in home Systolic Blood Pressure between 12 week treatments of irbesartan and telmisartan
- Secondary Outcome Measures
Name Time Method 1.To compare the percents of achieving blood pressure targets in home Blood Pressure monitoring between 12 week treatments of irbesartan and telmisartan 2.To compare the changes from baseline in office blood pressure, home diastolic Blood Pressure, heart rates between 12 week treatments of irbesartan and telmisartan 3.To compare the changes from baseline in LDL-C, HDL-C, TG, FFA, FBS, HbA1C, UACR between 12 week treatments of irbesartan and telmisartan 4.To compare the changes from baseline in blood and urine examinations between 12 week treatments of irbesartan and telmisartan